title: [Hepatitis C virus and chronic hepatopathies in Dakar: case-control study].
abstract: In Black Africa, the role of hepatitis C virus (HCV) in the onset of chronic hepatic disease is unclear. This is particularly true in Senegal where the prevalence of HCV is moderate. To gain insight into this question, a case-control study including 73 patients and 73 controls was carried out at Principal Hospital in Dakar in 1995. The patients included in this study presented chronic hepatitis in 2 cases cirrhosis in 25 and hepatocellular carcinoma in 46. Patients and controls underwent serologic testing for HCV (ELISA screening test followed by 3rd generation ELISA test in case of positive results and confirmation by immunoblot) with determination of HCV serotype using the immunoenzymatic method. Testing also included research for infection by hepatitis B virus and for anti-delta antibodies. Anti-HCV antibodies were detected in two patients (3 p. 100) and serology was suspicious in two others. Serotype 2 was detected in one of these patients. No positive results were recorded in controls. Fifty-four patients (74 p. 100) and 15 controls (21 p. 100) presented the HBs antigen including 13 patients (24 p. 100) and I control (7 p. 100) with anti-delta antibodies. This study shows that HCV currently plays a minor role in the onset of hepatic disease in hospitalized patients in Senegal. It also confirms the predominant role of hepatitis B and complicating effect of the delta hepatitis virus. These findings are compared with reported data for Black African countries. The impact of HCV appears to be lower in Senegal than in central Africa.
authors.affiliation: Service de Médecine Interne et d'Hépato-Gastroentérologie de l'Hôpital Principal de Dakar, Sénégal.
authors.forename: P S
authors.initials: PS
authors.lastname: Mbaye
authors.forename: Y
authors.initials: Y
authors.lastname: Renaudineau
authors.forename: A
authors.initials: A
authors.lastname: Diallo
authors.forename: D
authors.initials: D
authors.lastname: Haudrechy
authors.forename: M
authors.initials: M
authors.lastname: Sane
authors.forename: G
authors.initials: G
authors.lastname: Michel
authors.forename: G
authors.initials: G
authors.lastname: Raphenon
authors.forename: F
authors.initials: F
authors.lastname: Klotz
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000821:virology; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000145:classification; D006515:Hepatitis B virus; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000453:epidemiology / Q000821:virology; D003698:Hepatitis Delta Virus; D006801:Humans; D007124:Immunoenzyme Techniques; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000821:virology; D008107:Liver Diseases / Q000453:epidemiology / Q000821:virology*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000821:virology; D008297:Male; D008875:Middle Aged; D012675:Senegal / Q000453:epidemiology; D012703:Serotyping
chemical_list: D018937:Hepatitis C Antibodies